Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NHWD-870
- Development stage
- Phase 2
- Lead developer
- Zhejiang Wenda Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NHWD-870 is a potent, orally bioavailable bromodomain and extra-terminal (BET) inhibitor that exhibits selectivity for bromodomain containing 4 (BRD4). It was developed for anti-cancer potential and is more potent than clinical stage BET inhibitors such as birabresib and molibresib. NHWD-870 binds to bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. It has demonstrated efficacy in reducing tumor growth in multiple mouse models of cancers, including lung and ovarian tumors, lymphoma, and melanoma. Beyond oncology applications, research has shown potential applications in psoriasis treatment and as a male contraceptive.
- Other names
- NHWD-870 HClNHWD870 HClNHWD 870 HCl
02
Targets
BRD2 (Bromodomain-containing protein 2)KCNH2 (Voltage-gated potassium channel subfamily H member 2)BRD4 (Bromodomain-containing protein 4)BRDT (Bromodomain testis-specific protein)BRD3 (Bromodomain-containing protein 3)
Beyond the preview
Go deeper on NHWD-870.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NHWD-870.